Company profile: Multiplicom
1.1 - Company Overview
Company description
- Provider of molecular diagnostics products and clinical laboratory-based tests, including DNA/RNA library preparation and hybrid-capture target enrichment kits for Illumina sequencing. Offerings support low-input and FFPE samples, whole-genome and targeted sequencing, liquid biopsy applications, include molecular barcodes, and enable detection of low-frequency alleles.
Products and services
- SureSelectXT HS2 DNA Reagent Kit: A modular workflow library prep and target enrichment system for Illumina RNA/DNA sequencing with molecular barcodes enabling detection of low-frequency alleles
- SureSelectXT HS Reagent Kits: High-sensitivity DNA library prep kits featuring hybrid-capture target enrichment optimized for FFPE samples, with molecular barcodes measuring variant allele frequency down to 1% or less
- SureSelectXT Low Input Reagent Kits: Low-input DNA library prep with hybrid-capture target enrichment optimized for low-input FFPE samples, enabling high-quality libraries from as little as 10 ng DNA input
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Multiplicom
Diagnomics
HQ: United States
Website
- Description: Provider of NGS-based genomics solutions for personalized medicine and next-generation healthcare, offering high-quality R&D and CLIA services including whole genome, exome and RNA sequencing, microarray services, bioinformatics analysis, and clinical/translational research support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diagnomics company profile →
Translate Bio
HQ: United States
Website
- Description: Provider of biotechnology-driven RNA therapeutics focused on rare diseases, developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Translate Bio company profile →
Health in Code
HQ: Spain
Website
- Description: Provider of genetic diagnosis and testing services for inherited diseases, with expertise in inherited cardiovascular conditions. Services include full NGS testing from DNA reception to specialized clinical reports, in-house sequencing kits with bioinformatics and variant database, variant interpretation per guidelines, multidisciplinary clinical genetic reports, specialist genetic counseling, and proteomics as a certified Olink Explore service provider.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Health in Code company profile →
Verve Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage genetic medicines for cardiovascular disease, including gene editing therapies VERVE-101 targeting PCSK9 to lower LDL-C in heterozygous familial hypercholesterolemia and ASCVD, and VERVE-201 targeting ANGPTL3 for homozygous and refractory hypercholesterolemia, enabled by a proprietary GalNAc-LNP liver delivery system, with medicines evaluated in clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verve Therapeutics company profile →
Maze Therapeutics
HQ: United States
Website
- Description: Provider of precision medicines for renal, cardiovascular, and metabolic diseases, including MZE829, an oral candidate for APOL1 kidney disease that mimics protective genetic variants, and MZE001, an oral substrate reduction therapy for Pompe disease. Offers the Compass platform integrating variant functionalization into drug development and genetic medicine programs for chronic kidney and cardio-metabolic diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Maze Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Multiplicom
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Multiplicom
2.2 - Growth funds investing in similar companies to Multiplicom
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Multiplicom
4.2 - Public trading comparable groups for Multiplicom
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →